sotalol has been researched along with Cardiac Failure in 32 studies
Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Sotalol is a nonselective β-adrenergic receptor antagonist with class III antiarrhythmic properties that has been mostly used for atrial fibrillation treatment and suppressing recurrent ventricular tachyarrhythmias." | 9.41 | The Arrhythmogenicity of Sotalol and its Role in Heart Failure: A Literature Review. ( Alvarez, C; Augustin, N; Kluger, J, 2023) |
| "Key safety parameters of sotalol were examined in 1,288 patients entered into recent controlled trials of ventricular (85% of patients) or supraventricular arrhythmias (15%)." | 8.78 | Clinical safety profile of sotalol in patients with arrhythmias. ( Soyka, LF; Spangenberg, RB; Wirtz, C, 1990) |
| "This study was designed to determine the hemodynamic effects of the class III antiarrhythmic agent d-sotalol in acute ischemic heart failure at concentrations that prolong ventricular repolarization." | 7.68 | Hemodynamic effects of d-sotalol in acute ischemic heart failure in dogs. ( Kløw, NE; Mortensen, E; Refsum, H; Tande, PM, 1992) |
| " Sotalol is a nonselective β-adrenergic receptor antagonist with class III antiarrhythmic properties that has been mostly used for atrial fibrillation treatment and suppressing recurrent ventricular tachyarrhythmias." | 5.41 | The Arrhythmogenicity of Sotalol and its Role in Heart Failure: A Literature Review. ( Alvarez, C; Augustin, N; Kluger, J, 2023) |
| "Amiodarone pre-treatment led to a prolongation of APD(90) (+19 ms) as compared with sham-controlled hearts but showed only a marginal effect on APD(90) in failing hearts." | 5.37 | A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase-III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing-induced heart failure. ( Breithardt, G; Eckardt, L; Fehr, M; Frommeyer, G; Koopmann, M; Lücke, M; Milberg, P; Osada, N; Stypmann, J; Witte, P, 2011) |
| "A total of 55 patients with AF and/or CHF (New York Heart Association functional class > or =III) who had ICDs were divided into 3 groups [amiodarone (n=24), sotalol (n=12), beta-blocker (n=19)] and the cumulative rates of inappropriate shocks were compared." | 5.13 | Effects of antiarrhythmic drugs on inappropriate shocks in patients with implantable cardioverter defibrillators. ( Choi, KJ; Kim, HY; Kim, J; Kim, YH; Lee, CH; Nam, GB; Park, HG; Park, KM, 2008) |
| " β blockers, alone or in combination with digoxin, or non-dihydropyridine calcium-channel blockers (not in heart failure) effectively lower the heart rate." | 4.93 | Rate control in atrial fibrillation. ( Crijns, HJ; Olshansky, B; Rienstra, M; Van Gelder, IC, 2016) |
| "Key safety parameters of sotalol were examined in 1,288 patients entered into recent controlled trials of ventricular (85% of patients) or supraventricular arrhythmias (15%)." | 4.78 | Clinical safety profile of sotalol in patients with arrhythmias. ( Soyka, LF; Spangenberg, RB; Wirtz, C, 1990) |
| "In this clinical setting, we found that thiazides, vessel-active calcium channel blockers, and nonselective beta blockers (specifically sotalol) were associated with a lower risk of incident CHF among patients with atrial fibrillation." | 3.88 | Associations between relevant cardiovascular pharmacotherapies and incident heart failure in patients with atrial fibrillation: a cohort study in primary care. ( Ärnlöv, J; Carlsson, AC; Holzmann, MJ; Sundquist, J; Sundquist, K; Wändell, P, 2018) |
| "This study was designed to determine the hemodynamic effects of the class III antiarrhythmic agent d-sotalol in acute ischemic heart failure at concentrations that prolong ventricular repolarization." | 3.68 | Hemodynamic effects of d-sotalol in acute ischemic heart failure in dogs. ( Kløw, NE; Mortensen, E; Refsum, H; Tande, PM, 1992) |
| "Amiodarone has been demonstrated to be more efficacious than propafenone or sotalol in the Canadian Trial of Atrial Fibrillation." | 2.42 | Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. ( Bhatta, L; Hynes, J; Khan, M; Luck, J; Naccarelli, GV; Samii, S; Wolbrette, DL, 2003) |
| "These include catheter ablation of cardiac arrhythmias, certain surgical techniques that in selected patients offer prospects of cure, and the development of implantable ventricular and atrial cardioverter defibrillators, which allow the evaluation of drugs versus placebo against the background of the defibrillator." | 2.40 | Controlling cardiac arrhythmias: an overview with a historical perspective. ( Singh, BN, 1997) |
| " Investigators have hoped that these drugs would be as effective as sotalol and amiodarone but have fewer adverse effects." | 2.40 | The side effect profile of class III antiarrhythmic drugs: focus on d,l-sotalol. ( MacNeil, DJ, 1997) |
| "Amiodarone pre-treatment led to a prolongation of APD(90) (+19 ms) as compared with sham-controlled hearts but showed only a marginal effect on APD(90) in failing hearts." | 1.37 | A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase-III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing-induced heart failure. ( Breithardt, G; Eckardt, L; Fehr, M; Frommeyer, G; Koopmann, M; Lücke, M; Milberg, P; Osada, N; Stypmann, J; Witte, P, 2011) |
| " Rhythm control agents are associated with clinically important adverse events." | 1.36 | Rhythm control agents and adverse events in patients with atrial fibrillation. ( Hobbs, FD; Hodgkinson, J; Taylor, CJ, 2010) |
| "The other two presented in congestive cardiac failure." | 1.30 | Junctional ectopic tachycardia in six paediatric patients. ( Cilliers, AM; Clur, SA; Dateling, F; du Plessis, JP; Levin, SE, 1997) |
| "DL-Sotalol has class III antiarrhythmic activity through prolongation of the repolarization phase of the action potential as well as beta-adrenoceptor-blocking properties." | 1.29 | Positive and negative inotropic effects of DL-sotalol and D-sotalol in failing and nonfailing human myocardium under physiological experimental conditions. ( Fraedrich, G; Hasenfuss, G; Holubarsch, C; Just, H; Pieske, B; Posival, H; Ruf, T; Schneider, R, 1995) |
| "Chronic treatment of heart failure patients with beta-adrenoceptor antagonists leads to an up-regulation of cardiac beta-adrenoceptors, but in a subtype-selective fashion: beta 1-selective antagonists increase only cardiac beta 1-adrenoceptors, whereas non-selective antagonists increase both beta 1- and beta 2-adrenoceptors." | 1.28 | Drug- and disease-induced changes of human cardiac beta 1- and beta 2-adrenoceptors. ( Borst, HG; Brodde, OE; Maier, W; Michel, MC; Zerkowski, HR, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (9.38) | 18.7374 |
| 1990's | 10 (31.25) | 18.2507 |
| 2000's | 7 (21.88) | 29.6817 |
| 2010's | 9 (28.13) | 24.3611 |
| 2020's | 3 (9.38) | 2.80 |
| Authors | Studies |
|---|---|
| Augustin, N | 1 |
| Alvarez, C | 1 |
| Kluger, J | 1 |
| Deering, TF | 1 |
| Reiffel, JA | 1 |
| Solomon, AJ | 1 |
| Tamirisa, KP | 1 |
| Kobayashi, M | 1 |
| Kwak, MJ | 1 |
| Aguilar, D | 1 |
| Goyal, P | 1 |
| Holmes, HM | 1 |
| Deshmukh, AA | 1 |
| Aparasu, RR | 1 |
| Wändell, P | 1 |
| Carlsson, AC | 1 |
| Holzmann, MJ | 1 |
| Ärnlöv, J | 1 |
| Sundquist, J | 1 |
| Sundquist, K | 1 |
| Borchetta, K | 1 |
| Van Gelder, IC | 2 |
| Rienstra, M | 1 |
| Crijns, HJ | 2 |
| Olshansky, B | 1 |
| Newhard, D | 1 |
| Jung, S | 1 |
| Shimada, YJ | 1 |
| Sato, K | 1 |
| Hanon, S | 1 |
| Schweitzer, P | 1 |
| Taylor, CJ | 1 |
| Hodgkinson, J | 1 |
| Hobbs, FD | 1 |
| Frommeyer, G | 3 |
| Milberg, P | 3 |
| Witte, P | 1 |
| Stypmann, J | 3 |
| Koopmann, M | 1 |
| Lücke, M | 1 |
| Osada, N | 3 |
| Breithardt, G | 3 |
| Fehr, M | 1 |
| Eckardt, L | 3 |
| Pott, C | 1 |
| Fink, M | 1 |
| Ruhe, M | 1 |
| Matsuda, T | 1 |
| Baba, A | 1 |
| Klocke, R | 1 |
| Quang, TH | 1 |
| Nikol, S | 1 |
| Müller, FU | 1 |
| Noble, D | 1 |
| Clusin, WT | 1 |
| Rajamani, S | 1 |
| Grundmann, F | 1 |
| Belardinelli, L | 1 |
| Naccarelli, GV | 1 |
| Wolbrette, DL | 1 |
| Khan, M | 1 |
| Bhatta, L | 1 |
| Hynes, J | 1 |
| Samii, S | 1 |
| Luck, J | 1 |
| Tereshchenko, SN | 2 |
| Bulanova, NA | 1 |
| Kositsyna, IV | 1 |
| Morozova, MN | 2 |
| Uteshev, IuA | 2 |
| Chuich, NG | 1 |
| Kochetov, AG | 1 |
| Lee, CH | 1 |
| Nam, GB | 1 |
| Park, HG | 1 |
| Kim, HY | 1 |
| Park, KM | 1 |
| Kim, J | 1 |
| Choi, KJ | 1 |
| Kim, YH | 1 |
| Holubarsch, C | 1 |
| Schneider, R | 1 |
| Pieske, B | 1 |
| Ruf, T | 1 |
| Hasenfuss, G | 1 |
| Fraedrich, G | 1 |
| Posival, H | 1 |
| Just, H | 1 |
| Focaccio, A | 1 |
| Peeters, G | 1 |
| Movsesian, M | 1 |
| Roden, R | 1 |
| Eki, Y | 1 |
| Krall, J | 1 |
| Bristow, MR | 1 |
| Passaretti, B | 1 |
| Savasta, C | 1 |
| Sganzerla, P | 1 |
| Guazzi, MD | 1 |
| Gottlieb, SS | 1 |
| Singh, S | 1 |
| Munger, M | 1 |
| Eichhorn, EJ | 1 |
| Ilgenfritz, J | 1 |
| Hanyok, J | 1 |
| Singh, BN | 1 |
| MacNeil, DJ | 1 |
| Cilliers, AM | 1 |
| du Plessis, JP | 1 |
| Clur, SA | 1 |
| Dateling, F | 1 |
| Levin, SE | 1 |
| Tuinenburg, AE | 1 |
| Van Den Berg, MP | 1 |
| Brügemann, J | 1 |
| De Kam, PJ | 1 |
| Marill, KA | 1 |
| Runge, T | 1 |
| Schinz, A | 1 |
| Schnelle, K | 1 |
| Klein, G | 1 |
| Mortensen, E | 1 |
| Tande, PM | 1 |
| Kløw, NE | 1 |
| Refsum, H | 1 |
| Soyka, LF | 1 |
| Wirtz, C | 1 |
| Spangenberg, RB | 1 |
| Brodde, OE | 1 |
| Zerkowski, HR | 1 |
| Borst, HG | 1 |
| Maier, W | 1 |
| Michel, MC | 1 |
| Simpson, FO | 1 |
9 reviews available for sotalol and Cardiac Failure
| Article | Year |
|---|---|
The Arrhythmogenicity of Sotalol and its Role in Heart Failure: A Literature Review.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Heart Failure; Hum | 2023 |
Rate control in atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Age Factors; Amiodarone; Anti-Arrhythmia Agents; Atenolol; Atrial Fibri | 2016 |
Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Australia; Canada; Controlled Clinical Tria | 2003 |
[Chronic heart failure and atrial fibrilation: aspects of management].
Topics: Acute Disease; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmi | 2003 |
Controlling cardiac arrhythmias: an overview with a historical perspective.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Tria | 1997 |
The side effect profile of class III antiarrhythmic drugs: focus on d,l-sotalol.
Topics: Action Potentials; Amiodarone; Anti-Arrhythmia Agents; Female; Heart Conduction System; Heart Failur | 1997 |
Meta-analysis of the Risk of Torsades de Pointes in patients treated with intravenous racemic sotalol.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Female; Heart Failure; Humans; Infusions, Intravenous; | 2001 |
Clinical safety profile of sotalol in patients with arrhythmias.
Topics: Arrhythmias, Cardiac; Heart Failure; Humans; Sotalol | 1990 |
Beta-adrenergic receptor blocking drugs in hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Alprenolol; Antidepressive Agents; Antihy | 1974 |
3 trials available for sotalol and Cardiac Failure
| Article | Year |
|---|---|
[Effect of bisoprolol and sotalol on clinical status of patients with proximal form of atrial fibrillation and chronic heart failure].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atrial Fibrillation; Bisoprolol; Exercise Test; Female; He | 2007 |
Effects of antiarrhythmic drugs on inappropriate shocks in patients with implantable cardioverter defibrillators.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Defibril | 2008 |
Hemodynamic effects of the class III antiarrhythmic drug, d-sotalol, in patients with congestive heart failure.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Double-Blind Method; Electrocardiography; Fe | 1996 |
20 other studies available for sotalol and Cardiac Failure
| Article | Year |
|---|---|
Chapter 5: Guideline Recommendations: Which AAD and for Whom?
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Heart Failure; Humans; Sotalol; Stroke Volume; United S | 2023 |
Prescribing Trend of Inappropriate Medications in Outpatient Clinics for Older Adults With Heart Failure in the United States: NAMCS 2012 to 2016.
Topics: Aged; Ambulatory Care; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressi | 2021 |
Associations between relevant cardiovascular pharmacotherapies and incident heart failure in patients with atrial fibrillation: a cohort study in primary care.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atrial Fibrillation; Calcium Channel Blockers; | 2018 |
Case 1: Wheezing Unresponsive to Bronchodilators in a 4-month-old Boy.
Topics: Anti-Arrhythmia Agents; Atrial Flutter; Bronchiolitis; Bronchodilator Agents; Diagnosis, Differentia | 2015 |
What Is Your Diagnosis?
Topics: Animals; Aortic Dissection; Cat Diseases; Cats; Echocardiography; Enalapril; Furosemide; Heart Failu | 2017 |
Termination of recurrent ventricular tachycardia by continuous positive airway pressure ventilation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Cardiomyopathy, H | 2009 |
Rhythm control agents and adverse events in patients with atrial fibrillation.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Case-Control Studies; Female; | 2010 |
A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase-III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing-induced heart failure.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Electrocardiography; Female; He | 2011 |
Acute inhibition of the Na(+)/Ca(2+) exchanger reduces proarrhythmia in an experimental model of chronic heart failure.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Heart; Heart | 2012 |
Role of sodium/calcium exchange in heart failure-induced arrhythmias: a potential therapeutic target.
Topics: Animals; Heart; Heart Failure; Humans; Sodium-Calcium Exchanger; Sotalol | 2012 |
New insights into the beneficial electrophysiologic profile of ranolazine in heart failure: prevention of ventricular fibrillation with increased postrepolarization refractoriness and without drug-induced proarrhythmia.
Topics: Acetanilides; Action Potentials; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Electrocar | 2012 |
Positive and negative inotropic effects of DL-sotalol and D-sotalol in failing and nonfailing human myocardium under physiological experimental conditions.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Depression, Chemical; | 1995 |
Mechanism of action of OPC-8490 in human ventricular myocardium.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Action Potentials; Adult; Azetidines; Cardiotonic Agents; Cycli | 1996 |
Reversal of heart failure with sotalol in a case of incessant supraventricular tachycardia.
Topics: Adolescent; Anti-Arrhythmia Agents; Electrocardiography; Heart Failure; Humans; Male; Sotalol; Tachy | 1996 |
Junctional ectopic tachycardia in six paediatric patients.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Catheter Ablation; Child; Child, Pre | 1997 |
Lack of prevention of heart failure by serial electrical cardioversion in patients with persistent atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Electric Countershock | 1999 |
Which beta-blocker?
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Arrhythmias, Cardiac; Bradycardia; Heart Failure; Huma | 2001 |
[Proceedings: Echocardiography in the evaluation of drug therapy of cardiovascular diseases].
Topics: Cardiac Output; Digoxin; Drug Evaluation; Echocardiography; Heart Failure; Humans; Isoproterenol; My | 1975 |
Hemodynamic effects of d-sotalol in acute ischemic heart failure in dogs.
Topics: Acute Disease; Animals; Coronary Disease; Diastole; Disease Models, Animal; Dogs; Dose-Response Rela | 1992 |
Drug- and disease-induced changes of human cardiac beta 1- and beta 2-adrenoceptors.
Topics: Adolescent; Adult; Cardiomyopathy, Dilated; Child; Child, Preschool; Coronary Disease; Heart Failure | 1989 |